According to FutureWise analysis the market for Apixaban in 2023 is US$ 1.87 billion, and is expected to reach US$ 2.96 billion by 2031 at a CAGR of 5.90%.
Apixaban is a medication belonging to a class of drugs known as anticoagulants or direct oral anticoagulants (DOACs). It is sold under the brand name Eliquis, among others. Apixaban is mainly used to prevent blood clots and strokes in individuals with certain medical conditions, particularly those with atrial fibrillation and deep vein thrombosis (DVT) or pulmonary embolism (PE), which are conditions involving blood clots in the veins. Unlike older anticoagulants like warfarin, which require regular monitoring of blood levels and dose adjustments, apixaban is taken orally in a fixed dose, making it more convenient for patients.
Apixaban works by inhibiting a specific clotting factor in the blood called factor Xa. This factor plays an important part in the blood clotting process, so by inhibiting it, apixaban helps prevent the formation of blood clots. Apixaban is commonly available in tablet and capsule form for administration. Tablets are solid dosage forms made by compressing the active ingredient(s) with various excipients (fillers, binders, and sometimes coatings) into a compact, easily administered form. Tablets are designed to be swallowed whole and dissolve in the stomach or intestinal tract, allowing the medication to be absorbed. Capsules are typically made of a gelatin shell that contains the medication in either powder or liquid form. In the case of apixaban, the active ingredient is likely contained in the form of powder or granule within the capsule.
FutureWise Market Research has published a report that provides an insightful analysis apixaban market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts apixaban market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.